SCHEMBL3060239

SCHEMBL3060239

Cc1cc(F)cc(C(=O)N(C)C(CCN)Cc2ccccc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.38
BACE2 Q9Y5Z0 2/20 0.38
HCRTR1 O43613 2/20 0.37
HCRTR2 O43614 2/20 0.37
HTR1A P08908 1/20 0.36
ATM Q13315 1/20 0.35
PYGL P06737 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
ALPI P09923 1/20 0.35
PKM P14618 1/20 0.35
PTGS1 P23219 1/20 0.35
XIAP P98170 1/20 0.35
SLC7A5 Q01650 1/20 0.35
MMP2 P08253 1/20 0.34
ALDH1A1 P00352 1/20 0.34
RAB9A P51151 1/20 0.34
ANPEP P15144 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3050416 1.00 BACE1 (0.38) BACE1BACE2HCRTR1HCRTR2HTR1A
SCHEMBL3052731 0.93 HCRTR1 (0.39) BACE1HCRTR1HCRTR2HTR1AATM
SCHEMBL3057175 0.93 HCRTR1 (0.39) BACE1HCRTR1HCRTR2HTR1AATM
SCHEMBL3058423 0.92 BACE1 (0.42) BACE1BACE2HCRTR1HCRTR2HTR1A
SCHEMBL3045276 0.92 BACE1 (0.42) BACE1BACE2HCRTR1HCRTR2HTR1A
SCHEMBL3060236 0.86 BACE1 (0.38) BACE1BACE2HCRTR1HCRTR2HTR1A
SCHEMBL3050414 0.86 BACE1 (0.38) BACE1BACE2HCRTR1HCRTR2HTR1A
SCHEMBL3048345 0.86 HCRTR1 (0.41) HCRTR1HCRTR2HTR1AATMMEN1
SCHEMBL3048364 0.86 HCRTR1 (0.41) HCRTR1HCRTR2HTR1AATMMEN1
SCHEMBL3047223 0.85 HCRTR1 (0.45) HCRTR1HCRTR2HTR1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222396-A1 4-ARYL-BUTANE-1,3-DIAMIDES NOVARTIS AG (CH) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222396-A1 4-ARYL-BUTANE-1,3-DIAMIDES CYP11B2, CYP11B1, BBC3 BACE1 765/4885BACE2 671/4885HCRTR1 3230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.